Because AFP assessment is a simple and reproducible method to for the evaluation of the efficacy of combination treatment, our study demonstrates the feasibility of using the dynamic trend of AFP as an early biomarker for predicting survival outcomes after combination therapy in advanced HCC patients. This evidence concerns the gene AFP and hepatocellular carcinoma.